Epidemiological characterization and prognostic factors in patients with confirmed cerebral cryptococcosis in central Taiwan

Chang-Hua Chen¹,³,⁹*; Hiu-Ngar Sy²; Li-Jhen Lin³; Hua-Cheg Yen⁴; Shao-Hung Wang⁵; Wei-Liang Chen⁶; Yu-Min Chen⁷; and Yu-Jun Chang⁸

Abstract

Background: Cryptococcal meningitis is a deadly fungal infection. This study aimed to characterize the epidemiology of cerebral cryptococcosis and to define its prognostic factors.

Methods: This cross-sectional study collected clinical information from cryptococcal meningitis patients with confirmed cerebral cryptococcosis from 2006 to 2012 at the Changhua Christian Healthcare System to access prognostic factors.

Results: Fifty-nine adult cryptococcal meningitis patients were studied. The incidence at Changhua Christian Healthcare System was approximately 170 episodes per 100,000 patients within the studied period. Forty-one of 59 cryptococcal meningitis patients developed complications. Overall, 12 of 59 patients died, for a three-month mortality rate of 20.3%. Prognostic factors positively associated with the three-month mortality included age (>55 years), patient delay, prolonged delay by the doctor in administering antifungal agent therapy, duration of intensive care unit stay, chronic lung disease, cryptococcemia, headache, altered mental status, positive blood cultures, and high cerebrospinal fluid opening pressure (≥250 mm H2O).

Conclusions: We strongly recommend early administration of an antifungal agent to each suspected cryptococcal meningitis patient to decrease both the delay by doctors in administering therapy and the mortality risk. Aggressive and supportive care for severe cryptococcal meningitis patients is critical to decrease overall mortality from this infection.

Keywords: Cryptococcus neoformans, Cryptococcus gattii; Cryptococcosis, Meningitis, Outcome, Risk Assessment

Background

Cryptococcus neoformans-Cryptococcus gattii species complex is the ubiquitous encapsulated yeast that causes significant infections, ranging from asymptomatic pulmonary colonization to life-threatening meningoencephalitis [1]. Cryptococcosis is a severe opportunistic fungal infection causing morbidity and mortality and can manifest as meningitis, pneumonia, or cryptococccemia in both immunocompetent and immunocompromised hosts [2–5]. It is estimated that approximately one million cases and 625,000 deaths occur annually worldwide from cryptococcal meningitis (CM) among HIV-infected individuals, but only a few studies have estimated the incidence of CM among non-HIV-infected patients [3, 6]. CM is not uncommon in Taiwan, and 845 new cases were detected using the National Health Insurance Research Database between January 2000 and December 2007 [7]. Tseng et al. [4] reported that patients infected with C. gattii were more likely to reside in central Taiwan than those infected with C. neoformans, but there are few geographic evaluations of CM in central Taiwan.

Outcomes and treatment failure are usually associated with underlying conditions, a delay in diagnosis or absence of treatment with a fungicidal drug [8, 9]. However, prognostic factors have mostly resulted from reports of clinical trials conducted in earlier treatment periods and risks [3, 10–13]. Because medical and surgical advancements may not serve the rapidly growing high-risk population of patients, more data on the
current epidemiology and prognostic factors of CM are necessary.

Although many studies have evaluated CM, some lack confirmed case studies, contain only mycological data, only focus on HIV or post-transplantation status, or do not provide incidence estimates [2, 3, 5, 6, 9, 14, 15]. There has been no comprehensive study providing a risk assessment for CM. Furthermore, the underlying mechanisms of CM are not yet fully understood, and so the most effective means of prevention remains unknown.

CM infection is fatal without treatment. As a result, rapid recognition, diagnosis, and treatment are required. Little is known about CM in the central Taiwan population. Therefore, this study reports a retrospective cross-sectional study for patients with confirmed CM at Changhua Christian Healthcare System (CCHS) between 2006 and 2012 with two specific aims: to characterize the epidemiology of cerebral cryptococcosis at CCHS and to define prognostic factors associated with death from CM.

Methods
Setting and population
The population of Changhua, Nantou, and Yunlin counties is mostly served by the CCHS, which has maintained comprehensive clinical records since 1867. These three counties are located in central Taiwan and had a population of 1,362,563 in 2014. CCHS is a 3200-bed medical institute in central Taiwan. Changhua Christian Hospital, part of the CCHS, is a 1800-bed tertiary referral medical center located in northern Changhua County and has been a Joint Commission International–accredited hospital since 2009.

Microbiological evaluation, serological examinations, and antifungal susceptibility testing of Cryptococcus isolates
Cerebrospinal fluid (CSF) samples were routinely sent for tests to obtain complete white blood cell counts and differential counts, glucose and protein concentrations, and India ink stain and cultures. Urine, pus, lung, ascites, pleural effusion, lymph node, and/or other biopsy tissues and aspiration specimens were collected and submitted for culturing when indicated. Serum and CSF cryptococcal antigen titers were determined using commercial latex agglutination tests (Cryptococcus Antigen Latex Agglutination Test System, Immuno-Mycologics, Inc., USA). There was no difference in the culture and identification systems during the study period.

The blood and CSF specimens were cultured in the BD BACTEC FX (Becton Dickinson, USA) culture system, which is fully automated for microorganism growth detection. A yeast-like microorganism was detected by microscopic inspection after gram staining, and the growth characteristics were observed on agar plates. Further identification was performed using the API-32C (BioMerieux, France) yeast identification system. All blood isolates were stored at ~80 °C in a Thermo Scientific Forma (Thermo Fisher Scientific, USA) 900 series 955 model.

For drug susceptibility testing, all available stored isolates were thawed, inoculated in Sabouraud dextrose agar, and incubated at 35 °C for 72 h. The procedures were done according to the manufacturer’s Sensititre YeastOne protocol (TREK Diagnostic Systems, UK) [16]. Briefly, yeast colonies from the Sabouraud dextrose agar plates were placed into test tubes containing 10 µl normal saline and vortexed; the turbidity of the suspensions was adjusted to a 0.5 McFarland standard. The suspensions were then placed into the panel wells and incubated in a 35 °C incubator for 72 h. A control well without an antifungal agent (AFA) was used to ensure the quality of growth and purity. After incubation, the control suspension was subcultured onto another Sabouraud dextrose agar plate to ensure the growth of 10-80 pure colonies for each corresponding candida isolate. The panel wells were read and interpreted automatically using a Vizion instrument (Thermo Scientific Sensititre Vizion Digital MIC Viewing System, Thermo Fisher Scientific, UK).

Definitions
CM was defined as a CSF culture positive for C. neoformans-C. gattii species complex in this study. Time until diagnosis was defined by the duration of symptoms (in days), that is, the number of days between symptom onset and meeting of the case definition. Patient delay was defined as the interval between the onset of symptoms and initial presentation to the hospital. Delay by the doctor in administering AFA therapy was defined as the interval between the initial presentation to the hospital and the start of AFA. Prolonged delay was defined as a delay greater than the median. Delay by the doctor in administering steroid therapy was defined as the interval between the initial presentation to the hospital and the start of steroid therapy. Prolonged delay was defined as a delay greater than the median. The patients were divided into two groups: the deceased group (comprising patients who died within three months of CM diagnosis) and the survival group (comprising those still living after three months). The median of prolonged delay of AFA was six days. In terms of AFA administration, patients were divided into two groups: the delayed group was defined as those patients who received AFA more than six days after admission and the non-delayed group was defined as those patients who received AFA within six days of admission.
Case findings and analysis
Diagnosis of cryptococcosis was defined in this study according to a review of microbiological reports, The International Classification of Diseases, 9th revision (ICD-9). Cases were sorted in computerized indices by ICD-9 diagnosis in codes 117.5 and 321.0. The medical charts of CCHS employed were from January 1, 2006, to December 31, 2012 [17]. CM was defined as a CSF culture positive for C. neoformans-C. gattii species complex in this study, and the definitive diagnosis of CM was established based on the presence of symptoms and/or signs suggestive of meningitis, a CSF culture positive for C. neoformans-C. gattii species complex, and a CSF smear positive for India ink. Brain computed tomography and/or magnetic resonance imaging studies were performed on admission, at the discretion of the physician; and follow-up brain images were dependent on the physician’s decision.

Between January 2006 and December 2012, hospitalized patients aged more than 18 years and diagnosed with CM were recruited. Each patient had a medical chart, which contained medical diagnoses, surgical interventions, and other key information from the medical records. The medical records of all CM cases were manually reviewed by the primary investigator (CCH) to confirm the diagnosis using CCHS resources. Cases that were judged problematic were reviewed by the secondary investigator (SSY). Only the first CM episode in each person during the study period was included for statistical analyses. To calculate disease incidence, the entire admitted patient population of CCHS was considered at risk for infection. All Cryptococcus isolates cultured from CSF were considered clinically significant. CM was defined as the isolation of Cryptococcus from CSF in an adult patient (age ≥ 18 years) between January 1, 2006, and December 31, 2012. We excluded those patients who presented the following conditions: less than 18 years old, polymicrobial bacteremia (C. neoformans-C. gattii species complex with another pathogen), incomplete diagnosis codes, or inconsistency between the data from, ICD-9 diagnosis in codes 117.5 and 321.0 and the microbiological dataset.

Validity and reliability of methods
A small-scale validity study was performed on the case-finding procedures. The validity of the system was tested by a review of the complete medical charts of 59 individuals who did not have any relevant code in ICD-9. Records were obtained from the microbiological dataset on or before December 31, 2012 (the end of the study period). To examine the reliability of both the case-finding procedure and the diagnoses, all cases judged problematic by the infectious disease specialist (CCH) were evaluated. Among the 65 cases examined, the panel accepted 59 diagnoses (91 %) and revised six.

Evaluation and investigation
A standardized case report form was used to collect data on age, sex, site of involvement, underlying disease, clinical presentation, length of symptoms, diagnostic laboratory and radiographic reports, medical treatment, interventions, and outcomes [17]. Severity of stroke was defined according to the Canadian Neurological Scale [18]. Concomitant diseases included hypertension, chronic kidney disease, diabetes, hyperlipidemia, preexisting cardiovascular disease, and previous stroke. Hypertension, chronic kidney disease, diabetes, and hyperlipidemia were defined according to previous recommendations [19–22]. Stroke, heart failure, atrial fibrillation, and congestive heart failure were identified by taking a history and by reviewing the medical chart.

Treatment and follow-up
AFA was classified according to drugs administered for induction, consolidation, and chronic suppression [17]. Induction was defined by the initial drug given for more than three days [17]. Consolidation was defined as the therapy given following a response to the induction regimen [17]. Chronic suppression represented the ongoing maintenance of AFA given to patients without evidence of active disease [17]. The duration of AFA and the daily dose were recorded; and the primary outcome was the three-month mortality in this study. Mortality attributable to cryptococcosis was also analyzed. A follow-up record was maintained from the date of diagnosis to the date of death or to the date of the last available record. For the statistical analysis, mild to moderate sequelae and severe sequelae were regarded as poor brain outcomes.

Statistical analysis
Clinical, neuroradiological, and CSF data were compared between groups. The χ² or Fisher’s exact test was used for binary variables, and Student t-test was employed for age comparisons between the two groups. Because patient delay, delay by the doctor in administering AFA, delay by the doctor in administering corticosteroid therapy, and total delay were not normally distributed, the nonparametric Mann–Whitney test was used to compare delay differences between groups. Multivariable analyses for prognostic factors related to three-month mortality were performed using multiple logistic regression analysis. Odds ratios (ORs) and their corresponding 95 % confidence intervals (95 % CIs) were also estimated using ordinary logistic regression. After univariate estimates were calculated, ORs were obtained in multivariate models for all independent variables. A p value < 0.05 was considered statistically significant. All data were analyzed using the software SPSS (version 17).
Results and discussion

Patient characteristics: laboratory and radiographic findings

Sixty-five CM patients were enrolled during the study period, but because of incomplete data and inconsistent diagnosis, only 59 were analyzed. The incidence of CM in adults consulting CCHS was not increased, ranging from 168.9/100,000 patient in 2006 to 172.3/100,000 patient in 2012. There was no significant linear trend for an annual increase in CM across the study period. Of the 59 patients analyzed (Table 1), 43 (72.9 %) had diabetes mellitus, 12 (20.3 %) were HIV-positive, and 32 (54.2 %) had malignancies. Cryptococcemia was noted in 21 (35.6 %) and pulmonary cryptococcosis in 21 (35.6 %) patients.

Before admission, 26 (44.1 %) patients exhibited symptomatic headache, 21 (35.6 %) had fever, and 20 (33.9 %) had altered mental status. Twenty-six (44.1 %) patients showed a high CSF opening pressure (>180 mm H2O), and 18 (30.5 %) patients showed a CSF opening pressure higher than 250 mm H2O. Every patient received AFA. Thirty-nine (66.1 %) patients received amphotericin B deoxycholate (deoxy-AmB) or lipid formulation amphotericin B (lipid-AmB) with flucytosine (5-FC), 14 (23.7 %) patients received deoxy-AmB or lipid-AmB with fluconazole (FLU), and six (10.2 %) patients received FLU alone. Forty-one (69.5 %) CM patients developed complications, including 41 with respiratory failure, 29 with hydrocephalus, 19 with hepatitis, and six with stroke. Eleven (44 %) of the 25 patients with hydrocephalus underwent an operation. Overall, 12 of the 59 CM patients died, for an overall mortality rate of 20.3 %.

Of the 59 CM patients, a cryptococcal antigen (CrAg) titer from either serum or CSF was elevated in every patient (Table 1). Fifteen (25.4 %) and 14 (23.7 %) patients showed elevated titers (>1:512) in serum and CSF, respectively. Median serum CrAg was 1:256 (interquartile range 1:16–1:2,048) and median CSF CrAg was 1:256 (interquartile range 1:16–1:2,048). The proportion of patients with positive CSF cultures was similar across groups, 82-86 % (p = 0.722). All 59 CM patients received a head computed tomography or brain magnetic resonance imaging; 29 (49.2 %) patients demonstrated hydrocephalus, 6 (10.2 %) had cryptococcoma, 10 (17.0 %) had basal meningeal enhancement, and 14 (23.7 %) were normal.

As we know, this is the first study to evaluate the risk factors and clinical outcomes of CM patients in central Taiwan.

Treatment and outcomes

As to induction therapy, 39 (66.1 %) patients received a combination of either deoxy-AmB or lipid-AmB plus 5-FC. Fourteen (23.7 %) patients received a combination of deoxy-AmB or lipid-AmB plus FLU. Finally, six (10.2 %) received FLU alone. Most patients received a 200–400 mg average daily dose of FLU. Comparison of induction regimens with combination therapy, as measured by the three-month mortality, is presented in Table 2.

In this study, 20.3 % of CM patients died within three months, which is a lower percentage than that in Tseng’s previous report [5]. The present study is a large, single-site, cross-sectional series of well-described, confirmed CM cases in a population that focuses on the prognostic factors associated with mortality. Factors observed associated with mortality included monotherapy, respiratory failure, cryptococcemia, length of stay in the ICU, baseline high CSF opening pressure (≥250 mm H2O), patient delay, prolonged delay by the doctor in administering AFA, and age (>55 years). On the other hand, mortality was not related to neuroradiological findings (basal meningeal enhancement, hydrocephalus, and cryptococcoma) or CSF CrAg titer, cerebral stoke, or antifungal susceptibility tests.

Prognostic factors

Table 1 summarizes the important clinical, neuroradiological, and CSF findings in both groups. A three-month mortality rate was 20.3 % among all patients. Twenty deaths (60 %) were attributable to cryptococcosis, according to available data. In univariate analyses, prognostic factors associated with three-month mortality included age (>55 years) (p = 0.192), length of stay in the intensive care unit (ICU; p < 0.001), chronic lung disease (p = 0.024), cryptococcemia (p = 0.032), headache (p = 0.031), altered mental status (p = 0.005), and high CSF opening pressure (≥250 mm H2O) (p = 0.032).

In multivariate logistic regression analyses, monotherapy (OR 16.5, 95 % CI 2.257–120.639, p = 0.006), respiratory failure (OR 5.217, 95 % CI 1.030–26.425, p = 0.046), cryptococcemia (OR 5.09, 95 % CI 2.540–10.220, p < 0.001), ICU length of stay (OR 4.217, 95 % CI 1.030–23.025, p = 0.034), baseline high CSF opening pressure (≥250 mm H2O) (OR 2.93, 95 % CI 1.25–6.88, p = 0.013), and age (>55 years) (OR 1.07, 95 % CI 1.030–1.146, p = 0.019) were associated with increased odds of mortality.

Table 2 summarizes the risk factors for mortality in both groups. The median delay by the doctor in administering AFA therapy for all patients was six days, and the median delay by the doctor in administering corticosteroid therapy among corticosteroid-treated patients was eight days; these values were set as the cutoff points to define prolonged delays by the doctors.

There was no difference in the durations of delay by the doctors in administering AFA therapy (p = 0.484) or corticosteroids (p = 0.022) between the two groups. After univariate logistic regression analysis, the OR for
| Variables                                                      | Survivor group | Deceased group | Total | p value | OR     | 95 % CI        | p value |
|---------------------------------------------------------------|----------------|----------------|-------|---------|--------|----------------|---------|
| **n = 47 (%)**                                                | 18             | 2              | 20    | 0.192   | 1.077  | 1.013–1.146    | 0.019   |
| **n = 12 (%)**                                                | 28 (59.6)      | 10 (83.6)      | 38    | 0.182   |        |                |         |
| **n = 59**                                                    |                |                |       |         |        |                |         |
| Age > 55 years                                                | 18             | 2              | 20    | 0.192   | 1.077  | 1.013–1.146    | 0.019   |
| Gender – male                                                 | 28 (59.6)      | 10 (83.6)      | 38    | 0.182   |        |                |         |
| Prior cryptococcal infection, not related to this episode     | 11 (23.4)      | 2 (16.7)       | 13    | 0.762   |        |                |         |
| Length of stay in the ICU (days), median (range)             | 5 (1–21)       | 8 (1–48)       | –     | <0.001  | 5.217  | 1.030–26.425   | 0.046   |
| Underlying disease                                           |                |                |       |         |        |                |         |
| DM                                                           | 34 (72.3)      | 9 (75.0)       | 43    | 0.052   |        |                |         |
| HTN                                                           | 31 (66.0)      | 6 (50.0)       | 37    | 0.334   |        |                |         |
| Chronic lung disease                                         | 20 (42.6)      | 9 (75.0)       | 29    | 0.024   | 0.34   | 0.100–1.240    | 0.09    |
| Hyperlipidemia                                                | 26 (55.3)      | 6 (50.0)       | 32    | 0.102   |        |                |         |
| Previous TB infection                                        | 2 (4.3)        | 1 (8.3)        | 3     | 0.203   |        |                |         |
| CV disease                                                    | 26 (55.3)      | 4 (33.3)       | 30    | 1       |        |                |         |
| Renal disease                                                 | 16 (34.0)      | 4 (33.3)       | 20    | 0.102   |        |                |         |
| Malignancy, other than hematological malignancy               | 26 (55.3)      | 6 (50.0)       | 32    | 0.102   |        |                |         |
| Hematological malignancy                                     | 25 (53.2)      | 5 (41.7)       | 30    | 0.181   |        |                |         |
| Hematological disease                                        | 23 (48.9)      | 5 (41.7)       | 28    | 1       |        |                |         |
| Autoimmune disease                                           | 23 (48.9)      | 3 (25.0)       | 26    | 0.591   |        |                |         |
| Psychiatric disease                                          | 23 (48.9)      | 3 (25.0)       | 26    | 0.591   |        |                |         |
| HIV                                                          | 16 (34.0)      | 5 (41.7)       | 21    | 1       |        |                |         |
| Site of infection                                             |                |                |       |         |        |                |         |
| Pulmonary cryptococcosis                                      | 13 (27.7)      | 8 (66.7)       | 21    | 0.074   | 0.44   | 0.180–1.070    | 0.07    |
| Cryptococcemia                                                | 12 (25.5)      | 9 (75.0)       | 21    | 0.032   | 5.09   | 2.540–10.220   | <0.001  |
| Clinical presentation                                        |                |                |       |         |        |                |         |
| Fever                                                         | 15 (31.9)      | 6 (50.0)       | 21    | 0.315   |        |                |         |
| Malaise                                                       | 13 (27.7)      | 2 (16.7)       | 15    | 0.381   |        |                |         |
| Weight loss                                                   | 12 (25.5)      | 1 (8.3)        | 13    | 0.281   |        |                |         |
| Headache                                                     | 24 (51.1)      | 2 (16.7)       | 26    | 0.031   | 3.3    | 0.696–15.642   | 0.133   |
| Visual change                                                 | 7 (14.9)       | 1 (8.3)        | 8     | 0.67    |        |                |         |
| Cranial nerve palsy                                          | 2 (4.3)        | 2 (16.7)       | 4     | 1       |        |                |         |
| Cough                                                        | 10 (21.3)      | 2 (16.7)       | 12    | 1       |        |                |         |
| Dyspnea                                                      | 9 (19.1)       | 1 (8.3)        | 10    | 1       |        |                |         |
| Altered mental status                                        | 12 (25.5)      | 8 (66.7)       | 20    | 0.005   | 4.09   | 1.540–9.220    | <0.001  |
| Abdominal pain                                                | 42 (89.4)      | 8 (66.7)       | 50    | 0.083   |        |                |         |
| Decreased urine output                                       | 24 (51.1)      | 4 (33.3)       | 28    | 0.109   |        |                |         |
| Diagnostic criteria                                          |                |                |       |         |        |                |         |
| Serum CrAg                                                    | 13 (27.7)      | 2 (16.7)       | 15    | 0.381   |        |                |         |
| CSF CrAg >1:512                                               | 10 (21.3)      | 4 (33.3)       | 14    | 0.281   |        |                |         |
| CSF white cell count (cell/mm³) (mean, SD)                   | 83.4 ± 32.6    | 80.4 ± 30.6    | –     | 0.849   |        |                |         |
| CSF % lymphocytes (mean, SD)                                 | 207.4 ± 109.8  | 177.4 ± 82.8   | –     | 0.781   |        |                |         |
| CSF protein (mg/dL; mean, SD)                                | 0.25 ± 0.22    | 0.22 ± 0.20    | –     | 0.35    |        |                |         |
| CSF blood glucose (mean, SD)                                 | –94 ± 175.1    | –90 ± 155.2    | –     | 0.674   |        |                |         |
| CSF response (day 14 vs. day 1; mean, SD)                    | 83.4 ± 32.6    | 80.4 ± 30.6    | –     | 0.943   |        |                |         |
| CSF opening pressure > 250 mm H₂O                            | 12 (25.5)      | 6 (50.0)       | 18    | 0.032   | 2.93   | 1.250–6.880    | 0.023   |
monotherapy (OR 16.5, 95 % CI 2.257–120.639, p = 0.006), respiratory failure (OR 5.217, 95 % CI 1.030–26.425, p = 0.046), cryptococcemia (OR 5.09, 95 % CI 2.540–10.220, p < 0.001), length of stay in the ICU (OR 4.217, 95 % CI 1.030–23.025, p = 0.034), baseline high CSF opening pressure (≥250 mm H2O) (OR 2.93, 95 % CI 1.250–6.880, p = 0.013), patient delay (OR 1.87, 95 % CI 1.274–11.230, p = 0.008), prolonged delay by the doctor in administering AFA (OR 1.45, 95 % CI 1.080–12.070, p = 0.008), and age (>55 years) (OR 1.07, 95 % CI 1.030–1.146, p = 0.019) were significantly higher in patients presenting with headache and altered mental status, and high CSF opening pressure had an increased risk of death. The association between high intracranial pressure and mortality was expected because aggressive management of high intracranial pressure is known to be crucial. These results are consistent with those of published studies [23, 24]. Typical CM patients presenting with fever, headache, and severe CM disease will also present with an altered mental status. The results of our multivariate model were consistent with prior studies showing that an altered mental status increased the OR of death [2, 3, 25].

The present results showed increased risk of death among patients with cryptococcemia. These data are similar to that of Liao’s study [23]. The current finding having a strong association with three-month mortality was a positive blood fungal culture. The magnitude of these results at our institution may explain an emergence of patients with cryptococcemia. In the present data, the association of cryptococcemia with poorer outcome is perhaps not surprising because of its correlation with more severe and/or disseminated disease [3, 26]. The association between high intracranial pressure and mortality was expected, as discussed in the previous paragraph. Patients presenting with headache and altered mental status, features linked with elevated intracranial pressure, were associated with a high risk of mortality [3]. The results of the multivariate model were consistent with prior studies showing that altered mental status increased the OR of death [2, 3, 25]. A previous analysis of 52 patients with cryptococcemia diagnosed during 1981 and 2001 in Taiwan showed that cirrhosis and severity of sepsis were associated with 30-day mortality [26]. Nussbaum et al. evaluated 230 patients between 1997 and 2001 reported neurological signs and symptoms, abnormal neuroimaging, and hematological malignancy as predictors of 90-day mortality [27].

The results of our multivariate analyses revealed an association between the drugs used for induction and mortality, which is in contrast with the study by Sun et al. [28], in which patients who received lipid-AmB had reduced ORs of death. Studies in varied patient populations have shown a beneficial role for combination therapy with 5-FC; differential administration in those studies may have contributed to the apparent benefit of lipid-AmB [10, 13, 17]. The current data comparing six CM patients who received FLU monotherapy revealed a lower mortality rate than those that received combination therapy (OR 16.5, 95 % CI 2.257–120.63, p = 0.006; Table 2). The reason the previously mentioned six patients received FLU monotherapy was a lack of 5-FC in Taiwan during the early period of this study; in addition, it was not appropriate for them to receive deoxy-AmB because of renal function impairment.

The present analysis provides strengths over previous studies, but the observational design was limited by confounding indications. The results of some comparisons should be interpreted carefully, such as in the study by Bicanic et al. [29]. Those patients with non-CNS disease who received FLU alone had the lowest mortality, seemingly reflecting less severe underlying disease in contrast to that in therapeutic populations [29]. Clinicians’ perception of patients’ severity of illness and underlying diseases may have resulted in different management. Although several covariates were measured, there were others that were not. We treat patients with more complications and comorbidities at Changhua Christian Hospital in central Taiwan, representing a bias.

Another important strength of this study was selecting three-month mortality as the primary outcome rather than a mycological endpoint. Left untreated, CM is a uniformly fatal disease, but even with AFA treatment, the outcome is influenced by factors associated with the host, underlying disease, or the fungus [30]. Several

### Table 1 Comparison of key variables between the survivor and deceased groups of CM patients (Continued)

| Neuroradiological findings                  | Survivors | Deceaseds | p-value |
|--------------------------------------------|-----------|-----------|---------|
| Hydrocephalus                              | 20 (42.6) | 9 (75.0)  | 0.117   |
| Cryptococcoma                              | 4 (8.5)   | 2 (16.7)  | 0.589   |
| Neurosurgical intervention                 | 5 (10.6)  | 6 (50.0)  | 0.147   |
| Stroke                                     | 4 (8.5)   | 2 (16.7)  | 0.591   |

CI: confidence interval; CM: cryptococcal meningitis; CrAg: cryptococcal antigen; CSF: cerebrospinal fluid; CV: cardiovascular; DM: diabetes mellitus; HIV: human immunodeficiency virus; HTN: hypertension; ICU: intensive care unit; OR: odds ratio; SD: standard deviation; TB: tuberculosis
studies have confirmed that abnormal mental status, high cerebrospinal fungal burden (demonstrated by high cryptococcal antigen titers or colony-forming units), disseminated infection, symptomatic elevated intracranial pressure, low CSF leukocyte cell counts, lack of 5-FC treatment during induction phase, and induction treatment with low-dose FLU are factors associated with poor outcome of acquired immune deficiency syndrome-related CM [9, 12, 13, 26, 30–35]. Anecdotal reports have indicated benefit from using corticosteroids in severe cases of paradoxical cryptococcal immune reconstitution inflammatory syndrome; but steroids alone in the setting of persistent infection or relapse with FLU-resistant Cryptococcus can cause harm [36, 37]. There was no significant difference in the initial prescription of corticosteroid therapy between the two groups in our study. The decision to initiate

| Variables                                      | Survivor group | Deceased group | Total  | Univariate logistic regression analysis |
|------------------------------------------------|----------------|----------------|--------|----------------------------------------|
| Mean age (years ± SD)                          | n = 47 (%)     | n = 12 (%)     | n = 59 | p value | OR | 95 % CI | p value |
| Age > 55 years                                  | 53.5 ± 17.8    | 69.2 ± 15.6    | 56.7 ± 18.4 |               | 0.019 | 1.07 | 1.013-1.146 | 0.019 |
| Gender – male                                  | 32 (68.1)      | 10 (83.3)      | 43     | 0.182 | 1.07 | 1.013-1.146 | 0.019 |
| Patient delay                                  | 18 (38.3)      | 2 (16.7)       | 20     | 0.182 | 1.07 | 1.013-1.146 | 0.019 |
| Patient delay (days), median (range)           | 10 (1–124)     | 9 (1–91)       | 10 (1–124) | 0.389 |
| Delay by the doctor in administering AFA       | 28 (59.6)      | 10 (83.3)      | 38     | 0.012 | 1.87 | 1.274-11.230 | 0.015 |
| Delay by the doctor in administering AFA (days), median (range) | 6 (1–180) | 4 (1–28) | 6 (1–180) | 0.485 |
| Prolonged delay by the doctor in administering AFA therapy (>6 days) | 16 (34.0) | 7 (58.3) | 23 | 0.009 | 1.45 | 1.080-12.070 | 0.008 |
| Delay by the doctor in administering corticosteroid | 18 (38.3) | 5 (41.7) | 23 | 0.062 | 1.07 | 1.013-1.146 | 0.019 |
| Delay by the doctor in administering corticosteroid (days), median (range) | 8 (1–14) | 9 (1–28) | 8 (1–28) | 0.389 |
| Total delay                                    | 32 (68.1)      | 10 (83.3)      | 42     | 0.055 | 1.07 | 1.013-1.146 | 0.019 |
| Total delay (days), median (range)             | 19 (1–180)     | 17 (1–91)      | 19 (1–180) | 0.459 |
| Prior cryptococcal infection, not related to this episode | 11 (23.4) | 2 (16.7) | 13 | 0.762 | 1.07 | 1.013-1.146 | 0.019 |
| Length of stay in the ICU (days), median (range) | 5 (1–21) | 8 (1–28) | 5 (1–28) | <0.001 | 4.217 | 1.030-23.025 | 0.034 |
| Diagnostic criteria                            |               |               |        |        |      |      |        |
| Serum CrAg >1:512                               | 13 (27.7)      | 2 (16.7)       | 15     | 0.381 | 1.07 | 1.013-1.146 | 0.019 |
| CSF CrAg >1:512                                 | 10 (21.3)      | 4 (33.3)       | 14     | 0.281 | 1.07 | 1.013-1.146 | 0.019 |
| Initial CSF WBC count per mm³, median (range)   | 9 (0–51)       | 20 (0–250)     | 106    | 0.056 | 1.07 | 1.013-1.146 | 0.019 |
| CSF opening pressure > 250 mm H₂O               | 12 (25.5)      | 6 (50.0)       | 18     | 0.032 | 2.93 | 1.250-6.880 | 0.013 |
| Minimum inhibitory concentration of amphotericin B > 0.5 μg/mL | 1 (2.1) | 0 | 1 | 0.559 | 1.07 | 1.013-1.146 | 0.019 |
| Minimum inhibitory concentration of FLU >8 μg/mL | 1 (2.1) | 0 | 1 | 0.862 | 1.07 | 1.013-1.146 | 0.019 |
| On AFA                                         |               |               |        |        |      |      |        |
| Deoxy-AmbH or lipid-AmbH + 5-FC                 | 33 (70.2)      | 6 (50.0)       | 39     | 0.005 | 1.07 | 1.013-1.146 | 0.019 |
| Deoxy-AmbH or lipid-AmbH + FLU                 | 10 (21.3)      | 4 (33.3)       | 14     | 3.3 | 1.696-15.642 | 0.133 |
| FLU                                            | 2 (4.3)        | 4 (33.3)       | 6      | 16.5 | 2.257-120.639 | 0.006 |
| Complications                                  |               |               |        |        |      |      |        |
| Respiratory failure                            | 29 (61.7)      | 12 (100.0)     | 41     | <0.001 | 5.217 | 1.030-26.425 | 0.046 |
| Hydrocephalus                                   | 20 (42.6)      | 9 (75.0)       | 29     | 0.117 | 1.07 | 1.013-1.146 | 0.019 |
| Neurosurgical intervention                      | 5 (10.6)       | 6 (50.0)       | 11     | 0.147 | 1.07 | 1.013-1.146 | 0.019 |
| Hepatitis                                       | 15 (31.9)      | 4 (33.3)       | 19     | 1.07 | 1.013-1.146 | 0.019 |
| Stroke                                          | 4 (8.5)        | 2              | 6      | 0.591 | 1.07 | 1.013-1.146 | 0.019 |

5-FC: flucytosine; AFA: antifungal agent; deoxy-AmbH: amphotericin B deoxycholate; CI: confidence interval; CM: cryptococcal meningitis; CrAg: cryptococcal antigen; CSF: cerebrospinal fluid; FLU: fluconazole; ICU: intensive care unit; lipid-AmbH: lipid formulation amphotericin B; OR: odds ratio; SD: standard deviation
Table 3 Comparison of clinical features, laboratory findings, and outcomes between delayed and non-delayed groups of CM patients

| Variables                                      | Non-delayed group | Delayed group | Total | p value | OR    | 95 % CI       | p value |
|------------------------------------------------|-------------------|---------------|-------|---------|-------|---------------|---------|
| Mean age (years ± SD)                          | 51.5 ± 16.8       | 70.2 ± 15.6   | 56.7 ± 18.4 |         |       |               |         |
| Age > 55 years                                  | 14 (38.3)         | 6 (26.1)      | 20    | 0.182   |       |               |         |
| Gender – male                                  | 20 (55.6)         | 18 (78.3)     | 38    | 0.192   |       |               |         |
| Prior cryptococcal infection, not related to this episode | 8 (23.4)         | 5 (21.7)      | 13    | 1.000   |       |               |         |
| Length of stay in the ICU (days), median (range) | 5 (1–21)          | 7 (1–48)      | 33    | 0.275   |       |               |         |

Underlying disease

| DM                                            | 26 (71.5)         | 17 (75.0)     | 43    | 0.062   |       |               |         |
| HTN                                           | 26 (70.8)         | 12 (50.0)     | 37    | 0.234   |       |               |         |
| Chronic lung disease                          | 12 (32.6)         | 17 (75.0)     | 29    | 0.134   |       |               |         |
| Hyperlipidemia                                 | 22 (61.1)         | 10 (43.5)     | 32    | 0.123   |       |               |         |
| Previous TB infection                         | 2 (5.6)           | 1 (4.3)       | 3     | 0.103   |       |               |         |
| CV disease                                     | 17 (47.2)         | 13 (56.5)     | 30    | 1.000   |       |               |         |
| Renal disease                                  | 11 (30.6)         | 9 (39.1)      | 20    | 0.202   |       |               |         |
| Malignancy, other than hematological malignancy| 11 (30.1)         | 19 (83.3)     | 30    | 0.112   |       |               |         |
| Hematological malignancy                      | 9 (24.5)          | 19 (83.3)     | 28    | 0.181   |       |               |         |
| Hematological disease                         | 5 (13.7)          | 21 (91.7)     | 26    | 1.000   |       |               |         |
| Autoimmune disease                            | 2 (5.1)           | 19 (83.3)     | 21    | 0.059   |       |               |         |
| Psychiatric disease                            | 12 (33.3)         | 9 (39.1)      | 21    | 1.000   |       |               |         |
| HIV                                           | 8 (22.7)          | 4 (16.7)      | 12    | 1.000   |       |               |         |
| Site of infection                              |                   |               |       |         |       |               |         |
| Pulmonary cryptococcosis                       | 11 (30.6)         | 10 (43.5)     | 21    | 0.084   |       |               |         |
| Cryptococcemia                                 | 11 (30.6)         | 10 (43.5)     | 21    | 0.132   |       |               |         |
| Clinical presentation                         |                   |               |       |         |       |               |         |
| Fever                                         | 11 (31.9)         | 10 (43.5)     | 21    | 0.215   |       |               |         |
| Malaise                                       | 10                | 5 (21.7)      | 15    | 0.371   |       |               |         |
| Weight loss                                   | 10 (27.7)         | 5 (21.7)      | 15    | 0.181   |       |               |         |
| Headache                                      | 18 (51.1)         | 8 (34.8)      | 26    | 0.021   | 0.23  | 0.696-15.642  | 0.023   |
| Visual change                                  | 5 (14.9)          | 3 (13.0)      | 8     | 0.670   |       |               |         |
| Cranial nerve palsy                           | 2 (4.3)           | 2 (8.7)       | 4     | 1.000   |       |               |         |
| Cough                                         | 8 (21.3)          | 4 (17.4)      | 12    | 1.000   |       |               |         |
| Dyspnea                                       | 7 (19.1)          | 3 (13.0)      | 10    | 1.000   |       |               |         |
| Altered mental status                         | 11 (30.6)         | 9 (39.1)      | 20    | 0.011   | 1.311 | 1.516-5.642  | 0.0133  |
| Abdominal pain                                 | 35 (97.2)         | 15 (65.2)     | 50    | 0.093   |       |               |         |
| Decreased urine output                        | 13 (36.1)         | 15 (65.2)     | 28    | 0.209   |       |               |         |
| Diagnostic factors                            |                   |               |       |         |       |               |         |
| Serum CrAg 1:512                               | 10 (27.7)         | 5 (21.7)      | 15    | 0.381   |       |               |         |
| CSF CrAg >1:512                                | 9 (25.0)          | 5 (21.7)      | 14    | 0.281   |       |               |         |
| CSF opening pressure > 250 mm H_{2}O           | 10 (27.8)         | 8 (34.8)      | 18    | 0.185   |       |               |         |
| Neuroradiological findings                    |                   |               |       |         |       |               |         |
| Basal meningeal enhancement                   | 4 (11.1)          | 6 (26.1)      | 10    | 0.059   |       |               |         |
| Hydrocephalus                                  | 19 (52.8)         | 10 (43.5)     | 29    | 0.117   |       |               |         |
steroids was based on the combination of suspected ongoing CNS mass effect with surrounding edema. Most patients who eventually died were admitted to the ICU because of respiratory insufficiency [38]. The association between ICU length of stay and occurrence of respiratory failure, which are known to be crucial, and mortality was expected [3]. Our results were consistent with Knaus's report [38]. According to the original database, hospital mortality of patients with an acute physiology and chronic health evaluation II score of 15 was as high as 21 % [38, 39]. However, we did not calculate the ICU length of stay in conjunction with the acute physiology and chronic health evaluation II score in this study, so we were unable to analyze this in detail.

**Delayed group analysis**

Table 3 summarizes the clinical features and laboratory findings and outcomes in the delayed group and the non-delayed group. The median delay by the doctor in administering AFA therapy for all patients was six days; this value was set as the cutoff point to define prolonged delay by the doctor in administering AFA therapy. As a result, the delayed group was defined as those patients who received AFA more than six days after admission. There was a significant difference in the overall death rate (p = 0.09) between the two groups. Headache and altered mental status also differed statistically between the two groups. After univariate logistic regression analysis, the OR for mortality (OR = 1.45, 95 % CI 1.080-2.070, p = 0.008), altered mental status (OR = 1.311, 95 % CI 1.516-5.642, p = 0.013), and headache (OR = 0.23, 95 % CI 0.696-15.642, p = 0.023) were significantly different between the two groups.

The current study has several strengths. Most important was the quality and nearly complete evaluation of risk assessment variables for patients with confirmed CM using the dataset from CCHS. Previously reported CM geographic and demographic data presented variable results. The validated data of the present study showed the risk assessment for three-month mortality in patients with CM. The second strength of the present study is that it included patients with a diversity of disease severity (Tables 1 and 2). Third, CCHS provides both primary care and referred care in central Taiwan; hence, this study may be representative of CM patients in other Taiwanese locations. Fourth, we found an association between delay by the doctor in administering AFA therapy and the three-month mortality, although a causal relationship could not be established in this retrospective study. Fifth, our study involved the use of three-month mortality as the primary outcome rather than a surrogate mycological endpoint that may not be able to directly correlate to benefit or harm of clinical patients’ conditions. Last, our study provided the incidence data for CM during the study period; in adults consulting CCHS in 2012, the incidence of CM was 172.3/100,000 patient.

However, there are also some important limitations to this study, partly because of its retrospective nature. First, the causal relationship between AFA treatment and CM could not be precisely established. Second, we did not perform advanced molecular mycological studies for further evaluation. Kaocharoen et al. [40] showed a greater genetic diversity and a wider range of major molecular types between geographic areas. Further evaluation is needed for the molecular analysis. Last, we served patients with more complications and comorbidities at Changhua Christian Hospital in central Taiwan, representing a bias. Our data also reflected the biases of treatment choices at Changhua Christian Hospital, but limiting the study initially to a single center increased internal validity.

**Conclusions**

Deceased CM patients were found to be older than those who survived, and death was associated with monotherapy, respiratory failure, cryptococcaemia, length of stay in the ICU, baseline high CSF opening pressure (≥250 mm H$_2$O), patient delay, prolonged delay by the

| Table 3 | Comparison of clinical features, laboratory findings, and outcomes between delayed and non-delayed groups of CM patients (Continued) |
|---------|--------------------------------------------------------------------------------------------------------------------------|
|         | Delayed group | Non-delayed group | p-value | OR (95% CI) | p-value |
| Cryptococcoma | 2 (5.6) | 4 (17.4) | 0.009 | 1.45 (1.080-2.070) | 0.008 |
| Neurosurgical intervention | 4 (10.6) | 7 (30.4) | 0.147 |
| Mortality | 11 (30.6) | 10 (43.5) | 23 |

CT: confidence interval; CM: cryptococcal meningitis; CrAg: cryptococcal antigen; CSF: cerebrospinal fluid; CV: cardiovascular; DM: diabetes mellitus; HIV: human immunodeficiency virus; HTN: hypertension; ICU: intensive care unit; OR: odds ratio; SD: standard deviation; TB: tuberculosis
doctor in administering AFA, and age (>55 years). We strongly recommend early administration of AFA for each suspected CM patient as a means of decreasing both the delay by the doctor in beginning therapy and the risk of mortality. Controlling the high CSF pressure can also help alleviate CM’s morbidity and mortality. Furthermore, aggressive and supportive care for severe CM patients is critical to decreasing CM’s overall mortality.

Ethics committee approval
The present study was approved by the Changhua Christian Hospital Institutional Review Board (no. 131118).

Abbreviations
- 5-FC: Fluorocytosine; 95 % CI: 95 % confidence interval; AFA: Antifungal agents; CCCHS: Changhua Christian Healthcare System; CM: Cryptococcal meningitis; CrAg: Cryptococcal antigen; CSF: Cerebrospinal fluid; deoxy-AmB: Amphotericin B deoxycholate; HIV: Human immunodeficiency virus; ICU: Intensive care unit; lipid-AmB: Lipid formulation of amphotericin B; OR: Odds ratio; SD: Standard deviation.

Competing interests
The authors declare that there are no competing interests.

Authors’ contributions
CHC, HNS, JCY performed most clinical services. L.L. and SHW carried out the majority of microbiological examinations. WLC interpreted the medical images. CHC and YMC coordinated this study. YSC handled the statistical analysis. OHC wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments
Authors thank Clinical Microbiological Laboratory of Changhua Christian Hospital for providing the clinical isolates of Cryptococcus neoformans-Cryptococcus gattii species complex. This research project would not have been possible without the support of many people. The authors wish to express their gratitude to staffs of Division of Infectious Diseases, Division of Neurosurgery, Division of Critical Care Medicine, and Department of Neurology of Changhua Christian Hospital who were extremely helpful and offered patient care, invaluable assistance, and support.

Author details
1Division of Infectious Disease, Department of Internal Medicine, Changhua Christian Hospital, Changhua, 135 Nanhsiao Street, Changhua, Taiwan.
2Department of Neurology, Changhua Christian Hospital, Changhua, Taiwan.
3Infection Control Committee, Changhua Christian Hospital, Changhua, Taiwan.
4Department of Neurosurgery, Changhua Christian Hospital, Changhua, Taiwan.
5Department of Microbiology, Immunology and Biopharmaceuticals, National Chiayi University, Chiayi City, Taiwan.
6Department of Medical Imaging, Changhua Christian Hospital, Changhua, Taiwan.
7Department of Pharmacy, Changhua Christian Hospital, Changhua, Taiwan.
8Laboratory of Epidemiology and Biostatistics, Changhua Christian Hospital, Changhua, Taiwan.
9Department of Nursing, College of Medicine & Nursing, Hung Kuang University, Taichung, Taiwan.

Received: 30 October 2014 Accepted: 6 May 2015

Published online: 12 May 2015

References
1. Casadevall A, Perfect JR. Cryptococcus neoformans. Washington, DC: ASM Press; 1998.
2. Vilchez RA, Irisi W, Lacomis J, Costello P, Fung J, Kuene S. The clinical epidemiology of pulmonary cryptococcosis in non-AIDS patients at a tertiary care medical center. Medicine (Baltimore). 2001;80(5):308–12.
3. Briandine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in clinical features among patients with Cryptococcus according to immune status. PLoS One. 2013;8(3), e60431.
4. Tseng HK, Liu CP, Ho MW, Lu PL, Lo HJ, Lin YH, et al. Taiwan infectious diseases study network for Cryptococcosis. Microbiological, epidemiological, and clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997–2010. PLoS One. 2013;8(4), e61921.
5. Park BJ, Wannewmeier RA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(15):25–30.
6. Chen YY, Lai CH. Nationwide population-based epidemiologic study of cryptococcal meningitis in Taiwan. Neuroepidemiology. 2011;36(2):79–84.
7. Nucci M, Perfect JR. When primary antifungal therapy fails. Clin Infect Dis. 2008;46(9):1426–33.
8. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, et al. Fungal burden, early fungoidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007;45(1):6–80.
9. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, et al. A comparison of amphotericin B alone and combined with fluconazole in the treatment of cryptococcal meningitis. N Engl J Med. 1997;337(3):126–31.
10. Dismukes WE, Cloud G, Gallis HA, Kirkberg TM, Medoff G, Craven PC, et al. Treatment of cryptococcal meningitis with combination amphotericin B and fluconazole for four as compared with six weeks. N Engl J Med. 1987;317(6):334–41.
11. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS associated cryptococcal meningitis. N Engl J Med. 1992;326(2):83–9.
12. van der Heist CM, Saag MS, Cloud GA, Hamili RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1993;329(1):11–21.
13. Lee YC, Wang JT, Sun HY, Chen TC. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J Microbiol Infect. 2011;44(3):338–45.
14. Lai CC, Gau SJ, Hsuie PR. Fungemia caused by non-Candida species. J Microbiol Infect. 2012;45:262–3.
15. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition. CLSI document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
16. Cote R, Hachinski VC, Shoulavil BL, Norris JW, Wolfe C. The Canadian neurological scale: a preliminary study in acute-stroke. Stroke. 1986;17:371–7.
17. Perfect JR, Dismukes WE, Dummer F, Goldman DL, Graybill JR, Hamili RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010;50(3):291–322.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. 2003;42:1206–52.
19. Rukutowski M, Mann W, Derose S, Selavan D, Pascual N, Diesto J, et al. Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente. Am J Kidney Dis. 2009;53(3 Suppl 3):586–99.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001;285(19):2486–97.
21. Juarez DT, Senteil T, Tokumara S, Goo R, Davis JW, Mau MM. Factors associated with poor glycemic control or wide glycemic variability among diabetes patients in Hawaii, 2006–2009. Prev Chronic Dis. 2011;29, e120065.
22. Liao CH, Chi CY, Wang YJ, Tseng SW, Chou CH, Ho CM, et al. Different presentations and outcomes between HIV-infected and HIV-uninfected patients with cryptococcal meningitis. J Microbiol Infect. 2011;45(2):236–504.
23. Jongwutives U, Sungkanuparph S, Khiertbrakul S. Comparison of clinical features between cryptococcosis in human immunodeficiency virus (HIV)-positive and HIV-negative patients. Jpn J Infect Dis. 2008;61(1):115–5.
25. Jean SS, Fang CT, Shau WY, Chen YC, Chang SC, Hsueh PR, et al. Cryptococcaemia: clinical features and prognostic factors. QJM. 2002;95(8):511–8.
26. Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4(2), e21.
27. Nussbaum JC, Jackson A, Namarka D, Phulusa J, Kenala J, Kanyemba C, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis. 2010;50(3):338–44.
28. Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis. 2009;49(11):1721–8.
29. Bicanic TA, Muzoora C, Brouwer AE, Meintjes G, Longley N, Taseea K, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis. 2009;49(3):702–9.
30. Kambugu A, Meya DB, Reinh J, B’Brien M, Janoff EN, Ronald AR, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008;46(11):1694–701.
31. Antinori S, Gallimberti L, Magni C, Casella A, Vago L, Mainini F, et al. Cryptococcus neoformans infection in a cohort of Italian AIDS patients: natural history, early prognostic parameters, and autopsy findings. Eur J Clin Microbiol Infect Dis. 2001;20(10):711–7.
32. Loyse A, Wainwright H, Jarvis JN, Bicanic T, Rebe K, Meintjes G, et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS. 2010;24(3):405–10.
33. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363(9423):1764–7.
34. Bicanic T, Brouwer AE, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS. 2009;23(6):701–6.
35. Musubire AK, Meya BD, Mayanja-Kizza H, Lukande R, Wiesner LD, Bohjanen P, et al. Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings. Afr Health Sci. 2012;12(2):226–30.
36. Huys RMKG, Bremmer R, Enting RH, Sprenger HG, van Assen S. Return of meningeal symptoms in a patient treated for cryptococcal meningitis. J Neurol. 2007;254(10):1443–4.
37. van Berkel A, van Lieshout J, Hellegering J, van der Hoeven JG, Pickkers P. Causes of death in intensive care patients with a low APACHE II score. Neth J Med. 2012;70(10):455–9.
38. Knaus WA, Draper AE, Wagner DP, Zimmerman JE. APACHE II. A severity of disease classification system. Crit Care Med. 1985;13(10):818–29.
39. Meyer W, Costahead A, Jackson S, Huynd M, Costahead E. IberoAmerican cryptococcal study group: molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis. 2003;9(2):189–95.
40. Kocharoen S, Ngnamkultungroj P, Fircactive C, Trilles L, Piyabongkarn D, Banlunara W, et al. Molecular epidemiology reveals genetic diversity amongst isolates of the Cryptococcus neoformans/C. gattii species complex in Thailand. PLoS Negl Trop Dis. 2013;7(7), e2297.